The United States, United Kingdom, European Union, and India have collectively committed over $4.2 billion in new public funding to cancer vaccine research, manufacturing infrastructure, and clinical trial networks in the first quarter of 2026 alone — a concentration of government investment without precedent in the history of cancer immunotherapy that is reshaping the landscape of who...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)